CryoLogyx completes £500k seed funding round

NewsGuard 100/100 Score

CryoLogyx, a University of Warwick spinout redefining cell technology through cryopreservation, today announced the close of its oversubscribed seed funding round. The £500k GBP investment came from private UK business angels and the Wider Oxford Technology Angel Network (WOTAN), which includes previous investors Oxford Technology Management.

The funding will be used to support commercialization of the company’s innovative cryopreserved cell technology, scale up production of its assay-ready cells and expand its reach in the UK and Europe.

CryoLogyx was spun out from the University of Warwick in 2020 by CEO Dr Tom Congdon and CSO Prof Matt Gibson, who developed a unique cryopreservation method* based on over a decade of research. The company provides assay-ready, cryopreserved cells conveniently plated in a variety of formats and optimized for in vitro research.

Its proprietary macromolecule cryoprotectant technology, Cryoshield, significantly reduces post-thaw damage to allow for direct use of viable cells from the freezer in less than 24 hours, helping researchers save up to 90% of their time on routine cell culture tasks.

CryoLogyx’s range of frozen, ready-to-use adherent cell lines offers scientists an efficient, reliable, and cost-effective solution with enhanced reproducibility. This could help to support the development of new screening technologies and automation in drug discovery, as well as potential future diagnostic and cell therapy applications.

Most recently, the ready-to-use cells enabled scientists at the Warwick Antimicrobial Screening Service to deliver a typical four-week project in four days.

The latest funding follows earlier investment from Oxford Technology Management and private investors, alongside a £300K grant from Innovate UK in 2021. It will allow CryoLogyx to expand its team and scale production of its pioneering cell-based assays to meet increasing demand from the UK and European markets.

It will also support the company’s R&D program, allowing it to accelerate the development and commercialization of new products and services, broadening its offering to existing and prospective customers, and opening up opportunities for global partnerships.

We are grateful to our business angel investors and WOTAN for their confidence and continued support in the company's growth. CryoLogyx is proud to be empowering scientists to conduct research more efficiently using our cryopreserved, assay-ready cells and this funding will help us scale operations to ensure we meet researchers’ needs and expand our reach into new markets.

Dr. Tom Congdon, CEO and Co-founder, CryoLogyx

Dr. Tim Hart, Director of Warwick Innovations, who is working with CryoLogyx to commercialize its technology, said: “This funding boost is a testament to the company's potential and reflects the trust investors have in CryoLogyx’s vision and leadership. It’s a truly remarkable technology with the potential to significantly reduce the experimental burden on researchers and expedite the discovery of lifesaving diagnostics and therapies. I very much look forward to seeing the company continue to go from strength to strength.”

CryoLogyx will showcase current and upcoming innovative products at ELRIG Research & Innovation 2024 taking place from 20–21 March in Manchester, UK. Visit the team at booth TBBZ2 in the TechBio Breakthrough Zone to find out more.

*Tomás et al., Assay-ready Cryopreserved Cell Monolayers Enabled by Macromolecular Cryoprotectants, Biomacromolecules (2022)



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research validates anti-inflammatory properties of wine using urinary tartaric acid as biomarker